Screen Savers. Win Wallpaper. Mac Wallpaper. Movie Gallery. Lysosomes The main function of these microscopic organelles is to serve as digestion compartments for cellular materials that have exceeded their lifetime or are otherwise no longer useful. Send us an email. Davidson and The Florida State University. All Rights Reserved. No images, graphics, software, scripts, or applets may be reproduced or used in any manner without permission from the copyright holders. Use of this website means you agree to all of the Legal Terms and Conditions set forth by the owners.
Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell , — Aflaki, E. The complicated relationship between Gaucher disease and parkinsonism: insights from a rare disease. Dehay, B. Webb, J. Cuervo, A. Xilouri, M. Mak, S. Lysosomal degradation of alpha-synuclein in vivo. Sevlever, D. Biochemistry 47 , — Vidoni, C. The role of cathepsin D in the pathogenesis of human neurodegenerative disorders.
Cullen, V. Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Brain 2 , 5—5 Caron, N. Therapeutic approaches to Huntington disease: from the bench to the clinic. Del Toro, D. Cell 20 , — Nakanishi, H. Age-related changes in activities and localizations of cathepsins D, E, B, and L in the rat brain tissues.
Liang, Q. Reduction of mutant huntingtin accumulation and toxicity by lysosomal cathepsins D and B in neurons. Qin, Z. Autophagy regulates the processing of amino terminal huntingtin fragments. Kim, Y. Lysosomal proteases are involved in generation of N-terminal huntingtin fragments. Ratovitski, T. Cysteine proteases bleomycin hydrolase and cathepsin Z mediate N-terminal proteolysis and toxicity of mutant huntingtin.
Bhutani, S. Dysregulation of core components of SCF complex in poly-glutamine disorders. Cell Death Dis. Ravikumar, B. Rab5 modulates aggregation and toxicity of mutant huntingtin through macroautophagy in cell and fly models of Huntington disease. Cell Sci.
Qi, L. Koga, H. A photoconvertible fluorescent reporter to track chaperone-mediated autophagy. The role of chaperone-mediated autophagy in huntingtin degradation. Bauer, P. Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. Trajkovic, K. Erie, C. Usenovic, M. Sweeney, P. Protein misfolding in neurodegenerative diseases: implications and strategies. Martini-Stoica, H. The autophagy—lysosomal pathway in neurodegeneration: a TFEB perspective.
Trends Neurosci. Torra, A. TFEB dysregulation as a driver of autophagy dysfunction in neurodegenerative disease: molecular mechanisms, cellular processes, and emerging therapeutic opportunities. Wang, H. Vakifahmetoglu-Norberg, H. Pharmacologic agents targeting autophagy. Autophagy in the renewal, differentiation and homeostasis of immune cells. Brady, R. Enzyme replacement for lysosomal diseases. Jurecka, A. Enzyme replacement therapy: lessons learned and emerging questions.
Expert Opin. Orphan Drugs 3 , — Safary, A. Enzyme replacement therapies: what is the best option? BioImpacts 8 , — Spada, M. Early higher dosage of alglucosidase alpha in classic Pompe disease. Lee, B. Medicine Baltimore 96 , e Renna, M. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. Rubinsztein, D. Autophagy modulation as a potential therapeutic target for diverse diseases.
Yin, H. The therapeutic and pathogenic role of autophagy in autoimmune diseases. Retnakumar, S. Pharmacological autophagy regulators as therapeutic agents for inflammatory bowel diseases. Ziegler, H. Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells.
USA 79 , — Xiu, Y. Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation. Vomero, M. Autophagy and rheumatoid arthritis: current knowledges and future perspectives.
Kuznik, A. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. Sumpter, M. Evidence for risk of cardiomyopathy with hydroxychloroquine. Lupus 21 , — McAfee, Q. Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency.
USA , — Maiuri, M. Autophagy Networks in Inflammation Springer, Xu, M. A phenotypic compound screening assay for lysosomal storage diseases. The biomolecular corona is retained during nanoparticle uptake and protects the cells from the damage induced by cationic nanoparticles until degraded in the lysosomes.
Nanomedicine 9 , — Bandyopadhyay, D. Lysosome transport as a function of lysosome diameter. Valdor, R. Chaperone-mediated autophagy regulates T cell responses through targeted degradation of negative regulators of T cell activation. This article is the first demonstration that CMA plays an important role in T cell immune regulation in vivo. Sardiello, M. A gene network regulating lysosomal biogenesis and function.
This article reveals that a highly coordinated gene network, regulated by the master regulator TFEB, exists in lysosomes, and that regulating this gene network via TFEB may provide a potential therapeutic strategy. Life Sci. Diwu, Z. A novel acidotropic pH indicator and its potential application in labeling acidic organelles of live cells. Ma, L. Live-cell microscopy and fluorescence-based measurement of luminal pH in intracellular organelles.
Cell Dev. Aits, S. Sensitive detection of lysosomal membrane permeabilization by lysosomal galectin puncta assay. This article elegantly decsribes a novel, specific and practical tool to detect lysosomal membrane permeabilization.
Zhou, J. Activation of lysosomal function in the course of autophagy via mTORC1 suppression and autophagosome-lysosome fusion. Cell Res. Ono, K. Susceptibility of lysosomes to rupture is a determinant for plasma membrane disruption in tumor necrosis factor alpha-induced cell death.
Evaluation of acridine orange, LysoTracker Red, and quinacrine as fluorescent probes for long-term tracking of acidic vesicles. Cytometry Part A 85 , — Chaperone-mediated autophagy. Methods Mol. Methods to monitor chaperone-mediated autophagy. Methods Enzymol. Patel, B. Methods to study chaperone-mediated autophagy.
Methods 75 , — Klionsky, D. Guidelines for the use and interpretation of assays for monitoring autophagy. This article is a comprehensive and critical overview of the numerous methods and tools that are used for evaluating autophagy and lysosomal activity, and deciphers the complex mechanisms and pathways involved in the regulation of these processes.
Bowes, J. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Galluzzi, L. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death Cell Death Differ. Andrade, M. Substrate reduction therapy with miglustat in type 1 Gaucher disease in Spain. Blood , — Smid, B. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
Guerard, N. Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement.
Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects. Marshall, J. CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease. Piotrowska, E. Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: an open-label, pilot study in 10 pediatric patients.
Moskot, M. Entchev, E. Steet, R. Magalhaes, J. Effects of ambroxol on the autophagy—lysosome pathway and mitochondria in primary cortical neurons. Porto, C. Xiao, J. Flanagan, J. The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase.
Berardi, A. Matsuda, J. Chemical chaperone therapy for brain pathology in GM1-gangliosidosis. Takai, T. A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis. Thome, R. Dendritic cells treated with chloroquine modulate experimental autoimmune encephalomyelitis. Danza, A. Hydroxychloroquine for autoimmune diseases.
Lai, Z. Lancet , — Shao, P. Modulation of the immune response in rheumatoid arthritis with strategically released rapamycin. Matarrese, P. Cathepsin B inhibition interferes with metastatic potential of human melanoma: an in vitro and in vivo study.
Cancer 9 , Fox, C. Inhibition of lysosomal protease cathepsin D reduces renal fibrosis in murine chronic kidney disease. Ikeda, Y. Cathepsins B and L in synovial fluids from patients with rheumatoid arthritis and the effect of cathepsin B on the activation of pro-urokinase.
Yamada, A. Shah, P. A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney T cells. Saegusa, K. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. Nakagawa, T. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice.
Immunity 10 , — Rupanagudi, K. Hargreaves, P. Edman, M. Katunuma, N. Structure-based development of pyridoxal propionate derivatives as specific inhibitors of cathepsin K in vitro and in vivo. Stroup, G. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. Bone Miner. Nwosu, L. Analgesic effects of the cathepsin K inhibitor L in the monosodium iodoacetate model of osteoarthritis pain. PAIN Rep. Viswanathan, K. Nonpeptidic lysosomal modulators derived from Z-Phe-Ala-diazomethylketone for treating protein accumulation diseases.
ACS Med. Yuan, N. Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia. Haematologica , — Niikura, K. A vacuolar ATPase inhibitor, FR, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application.
Lebreton, S. Evaluating the potential of vacuolar ATPase inhibitors as anticancer agents and multigram synthesis of the potent salicylihalamide analog saliphenylhalamide.
Visentin, L. Aldrich, L. Discovery of a small-molecule probe for V-ATPase function. Grimm, C. Martin, S. Inhibition of PIKfyve by YM dysregulates autophagy and leads to apoptosis-independent neuronal cell death. Cai, X. Sands, B. Bowel Dis. Krausz, S.
Wen, W. VER, a small molecule inhibitor of HSP70 with potent anti-cancer activity on lung cancer cell lines. Yang, X. Gong, Z. Humanin is an endogenous activator of chaperone-mediated autophagy.
Hernandez, I. A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy. Lachmann, R. Treatments for lysosomal storage disorders.
Radin, N. Treatment of Gaucher disease with an enzyme inhibitor. Glycoconjugate J. Pineda, M. Miglustat in Niemann—Pick disease type C patients: a review. Hughes, D. Wise, A. Gaffke, L. How close are we to therapies for Sanfilippo disease? Brain Dis. Mohamed, F. Pharmaceutical chaperones and proteostasis regulators in the therapy of lysosomal storage disorders: current perspective and future promises.
Ortolano, S. Treatment of lysosomal storage diseases: recent patents and future strategies. Recent Pat. Immune Drug Discov. Pereira, D. Tuning protein folding in lysosomal storage diseases: the chemistry behind pharmacological chaperones.
Beck, M. Treatment strategies for lysosomal storage disorders. Child Neurol. Siklos, M. Cysteine proteases as therapeutic targets: does selectivity matter?
DeBerardinis, R. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature , — Demers-Lamarche, J. Loss of mitochondrial function impairs lysosomes. Denton, R. Regulation of mitochondrial dehydrogenases by calcium ions. Acta Bioenerget. Elbaz, Y. Staying in touch: the molecular era of organelle contact sites.
Trends Biochem. Elbaz-Alon, Y. A dynamic interface between vacuoles and mitochondria in yeast. Cell 30, 95— Fernandez-Mosquera, L. Acute and chronic mitochondrial respiratory chain deficiency differentially regulate lysosomal biogenesis. Gomes, L. During autophagy mitochondria elongate, are spared from degradation and sustain cell viability. Hackenbrock, C. Ultrastructural bases for metabolically linked mechanical activity in mitochondria.
Reversible ultrastructural changes with change in metabolic steady state in isolated liver mitochondria. PubMed Abstract Google Scholar.
Honscher, C. Cellular metabolism regulates contact sites between vacuoles and mitochondria. Cell 30, 86— Jaiswal, J. Membrane proximal lysosomes are the major vesicles responsible for calcium-dependent exocytosis in nonsecretory cells. Kasahara, A. Mitochondrial fusion directs cardiomyocyte differentiation via calcineurin and notch signaling.
Khacho, M. Mitochondrial dynamics impacts stem cell identity and fate decisions by regulating a nuclear transcriptional program. Cell Stem Cell 19, — Kilpatrick, B.
Cell Sci. Lim, C. The lysosome as a command-and-control center for cellular metabolism. Lloyd-Evans, E. The lysosomal storage disease continuum with ageing-related neurodegenerative disease. Ageing Res. Mailloux, R.
Unearthing the secrets of mitochondrial ROS and glutathione in bioenergetics. Mansueto, G. Transcription factor EB controls metabolic flexibility during exercise.
McWilliams, T. PINK1 and parkin: emerging themes in mitochondrial homeostasis. Medina, D. Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. Mirnikjoo, B. Mobilization of lysosomal calcium regulates the externalization of phosphatidylserine during apoptosis.
Morita, M. Cell 67, Mouton-Liger, F. Nunnari, J. And when they do that, they provide for the rest of the cell the nutrients that it needs to So, for example, if you can't do that, it can't break down large molecules into small molecules. You'll have storage of those large molecules, and this is a disease. There's also another type of lysosome storage disease in which the small molecules that are produced from those large molecules can't get out of the lysosome.
They're stored there because the transporters for moving these small molecules out are missing genetically.
0コメント